Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

CTLA-4 Control over Foxp3 + Regulatory T Cell Function

Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914

Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766

Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation

Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206

Plat-E: an efficient and stable system for transient packaging of retroviruses

MORITA, S., Kojima, T., & Kitamura, T. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301206 · Cited by 1,660

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967

CD28 and CTLA-4 coreceptor expression and signal transduction

Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898

Foxp3 + natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation

Onishi, Y., Fehervari, Z. T., Yamaguchi, T., & Sakaguchi, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711106105 · Cited by 754

B cells acquire antigen from target cells after synapse formation

Batista, F. D., Iber, D., & Neuberger, M. S. (2001) · Nature · doi:10.1038/35078099 · Cited by 629

A MOLECULAR PERSPECTIVE OF CTLA-4 FUNCTION

Teft, W. A., Kirchhof, M. G., & Madrenas, J. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090535 · Cited by 526

TCR Signaling and CD28/CTLA-4 Signaling Cooperatively Modulate T Regulatory Cell Homeostasis

Holt, M. P., Punkosdy, G. A., Glass, D. D., & Shevach, E. M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601670 · Cited by 53

Immune checkpoints and cancer development: Therapeutic implications and future directions

Mehdizadeh, S., Bayatipoor, H., Pashangzadeh, S., Jafarpour, R., Shojaei, Z., & Motallebnezhad, M. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153485 · Cited by 55

Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors

Roy, D., Gilmour, C., Patnaik, S., & Wang, L. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264327 · Cited by 53

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity

Watanabe, T., Ishino, T., Ueda, Y., Nagasaki, J., Sadahira, T., Dansako, H., Araki, M., & Togashi, Y. (2023) · Cancer Science · doi:10.1111/cas.15756 · Cited by 53

The Molecular Mechanisms of Regulatory T Cell Immunosuppression

Pandiyan, P., Zheng, L., & Lenardo, M. J. (2011) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00060 · Cited by 50

The “Trojan Horse” Approach to Tumor Immunotherapy: Targeting the Tumor Microenvironment

Nelson, D. J., Fisher, S. A., & Robinson, B. W. S. (2014) · Journal of Immunology Research · doi:10.1155/2014/789069 · Cited by 52

Immune checkpoint blockade: Releasing the brake towards hematological malignancies

Xia, Y., Medeiros, L. J., & Young, K. H. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.11.003 · Cited by 53

Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7

Halpert, M. M., Konduri, V., Liang, D., Chen, Y., Wing, J. B., Paust, S., Levitt, J. M., & Decker, W. K. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0009 · Cited by 52

A New VISTA on combination therapy for negative checkpoint regulator blockade

Deng, J., Mercier, I. L., Kuta, A., & Noelle, R. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0190-5 · Cited by 54

Common Features of Regulatory T Cell Specialization During Th1 Responses

Lambert, K., Moresi, C., Rakebrandt, N., Zhou, X., Schorer, M., Dolowschiak, T., Kirchner, F., Rost, F., Keller, C. W., McHugh, D., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01344 · Cited by 55

T cell costimulation, checkpoint inhibitors and anti-tumor therapy

Nandi, D., Pathak, S., Verma, T., Singh, M., Chattopadhyay, A., Thakur, S., Raghavan, A., Gokhroo, A., & Vijayamahantesh, V. (2020) · Journal of Biosciences · doi:10.1007/s12038-020-0020-2 · Cited by 58

Immunomodulatory role for MicroRNAs: Regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression

Skafi, N., Fayyad‐Kazan, M., & Badran, B. M. (2020) · Gene · doi:10.1016/j.gene.2020.144888 · Cited by 52

Combination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer – a brief update

Park, J., & Skålhegg, B. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680838 · Cited by 66

Th3 Immune responses in the progression of leprosy via molecular cross-talks of TGF-β, CTLA-4 and Cbl-b

Kumar, S., Naqvi, R. A., Khanna, N., Pathak, P., & Rao, D. N. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.06.007 · Cited by 56

Antigen-Specific Suppression and Immunological Synapse Formation by Regulatory T Cells Require the Mst1 Kinase

Tomiyama, T., Ueda, Y., Katakai, T., Kondo, N., Okazaki, K., & Kinashi, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073874 · Cited by 51

Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium

Kim, E. S., Kim, J. E., Patel, M. A., Mangraviti, A., Ruzevick, J., & Lim, M. K. (2016) · Journal of Immunology Research · doi:10.1155/2016/4683607 · Cited by 52

Characterization of CTLA4 Trafficking and Implications for Its Function

Khailaie, S., Rowshanravan, B., Robert, P. A., Waters, E., Halliday, N., Herrera, J. D. B., Walker, L. S. K., Sansom, D. M., & Meyer‐Hermann, M. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.08.020 · Cited by 49

Check Point Inhibitors and Their Role in Immunosuppression in Sepsis

Wakeley, M. E., Gray, C. C., Monaghan, S. F., Heffernan, D. S., & Ayala, A. (2019) · Critical Care Clinics · doi:10.1016/j.ccc.2019.08.006 · Cited by 58

The Role of Autophagy in Tumor Immunology—Complex Mechanisms That May Be Explored Therapeutically

de Souza, A. S. C., Gonçalves, L. B., Lepique, A. P., & de Araujo‐Souza, P. S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.603661 · Cited by 51

CD80 on Human T Cells Is Associated With FoxP3 Expression and Supports Treg Homeostasis

Soskic, B., Jeffery, L. E., Kennedy, A., Gardner, D. H., Hou, T. Z., Halliday, N., Williams, C., Janman, D., Rowshanravan, B., Hirschfield, G. M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577655 · Cited by 51

The paradox of immune checkpoint inhibition re-activating tuberculosis

Ahmed, M. I. M., Tezera, L. B., Elkington, P. T., & Leslie, A. J. (2022) · European Respiratory Journal · doi:10.1183/13993003.02512-2021 · Cited by 53

Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective

Sakaguchi, S., Kawakami, R., & Mikami, N. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad007 · Cited by 54

Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C

Losikoff, P. T., Self, A. A., & Gregory, S. H. (2012) · Virulence · doi:10.4161/viru.21823 · Cited by 51

Force Generation in B-Cell Synapses

Tolar, P., & Spillane, K. M. (2014) · Advances in immunology · doi:10.1016/b978-0-12-800266-7.00002-9 · Cited by 49

Regulatory T cells are essential to promote proper CD4 T-cell priming upon mucosal infection

Soerens, A. G., Costa, A. D. S., & Lund, J. M. (2016) · Mucosal Immunology · doi:10.1038/mi.2016.19 · Cited by 50

The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations

Terry, L. V., & Oo, Y. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.565518 · Cited by 51

Shaping of T Cell Functions by Trogocytosis

NAKAYAMA, M., Hori, A., Toyoura, S., & Yamaguchi, S.-I. (2021) · Cells · doi:10.3390/cells10051155 · Cited by 55

Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective

Amini, L., Kaeda, J., Fritsche, E., Roemhild, A., Kaiser, D., & Reinke, P. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1081644 · Cited by 53

Regulation of the tolerogenic function of steady‐state DCs

Probst, H. C., Muth, S., & Schild, H. (2014) · European Journal of Immunology · doi:10.1002/eji.201343862 · Cited by 51

Inducing and Administering Tregs to Treat Human Disease

Perdigoto, A. L., Chatenoud, L., Bluestone, J. A., & Herold, K. C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00654 · Cited by 51

Mechanisms of checkpoint inhibition-induced adverse events

Urwyler, P., Earnshaw, I., Bermudez, M., Perucha, E., Wu, W., Ryan, S. E., Mcdonald, L., Karagiannis, S. N., Taams, L. S., Powell, N., et al. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13421 · Cited by 48

Genomic variations and signatures of selection in Wuhua yellow chicken

Weng, Z., Xu, Y., Li, W., Chen, J., Zhong, M., Zhong, F., Du, B., Zhang, B., & Huang, X. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241137 · Cited by 51

Targeting CTLA ‐4 in cancer: Is it the ideal companion for PD ‐1 blockade immunotherapy combinations?

Silva, P. D., Aiello, M. M., Gu‐Trantien, C., Migliori, E., Willard-Gallo, K. E., & Solinas, C. (2020) · International Journal of Cancer · doi:10.1002/ijc.33415 · Cited by 49

Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4

Navarrete-Bernal, M. G. C., Cervantes-Badillo, M. G., Martínez‐Herrera, J. F., Lara-Torres, C. O., Gerson-Cwilich, R., Zentella‐Dehesa, A., Ibarra-Sánchez, M. D. J., Esparza‐López, J., Montesinos, J. J., Cortés-Morales, V. A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01206 · Cited by 50

CTLA4 depletes T cell endogenous and trogocytosed B7 ligands via cis-endocytosis

Xu, X., Dennett, P., Zhang, J., Sherrard, A., Zhao, Y., Masubuchi, T., Bui, J. D., Chen, X., & Hui, E. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221391 · Cited by 56

Defining Human Regulatory T Cells beyond FOXP3: The Need to Combine Phenotype with Function

Gootjes, C., Zwaginga, J. J., Roep, B. O., & Nikolić, T. (2024) · Cells · doi:10.3390/cells13110941 · Cited by 48

Cell‐extrinsic CTLA 4‐mediated regulation of dendritic cell maturation depends on STAT 3

Kowalczyk, A., D’Souza, C. A., & Zhang, L. (2013) · European Journal of Immunology · doi:10.1002/eji.201343601 · Cited by 48

Overcoming Tumor-Mediated Immunosuppression

Schlößer, H., Theurich, S., Shimabukuro‐Vornhagen, A., Holtick, U., Stippel, D. L., & von Bergwelt‐Baildon, M. (2014) · Immunotherapy · doi:10.2217/imt.14.58 · Cited by 49

Combination of Alphavirus Replicon Particle–Based Vaccination with Immunomodulatory Antibodies: Therapeutic Activity in the B16 Melanoma Mouse Model and Immune Correlates

Avogadri, F., Zappasodi, R., Yang, A. S., Budhu, S., Malandro, N., Hirschhorn-Cymerman, D., Tiwari, S., Maughan, M. F., Olmsted, R. A., Wolchok, J. D., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0220 · Cited by 48

Regulatory T cells: Master thieves of the immune system

Akkaya, B., & Shevach, E. M. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104160 · Cited by 52

Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis

Jiménez-Alejandre, R., Ruiz‐Fernández, I., & Martín, P. (2022) · Cancers · doi:10.3390/cancers14184494 · Cited by 50

Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma

Yan, Z., Dong, Y., Qiao, N., Zhang, Y., Wu, W., Zhu, Y., Wang, L., Cheng, S., Xu, P.-P., Zhou, Z., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49495-4 · Cited by 48

Regulatory T cells suppress CD4+ T cells through NFAT‐dependent transcriptional mechanisms

Shin, D. S., Jordan, A., Basu, S., Thomas, R. M., Bandyopadhyay, S., de Zoeten, E. F., Wells, A. D., & Macián, F. (2014) · EMBO Reports · doi:10.15252/embr.201338233 · Cited by 46

IL-21 Promotes CD4 T Cell Responses by Phosphatidylinositol 3-Kinase–Dependent Upregulation of CD86 on B Cells

Attridge, K., Kenefeck, R., Wardzinski, L., Qureshi, O., Wang, C. J., Manzotti, C. N., Okkenhaug, K., & Walker, L. S. K. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302082 · Cited by 46

Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia

Knaus, H. A., Kanakry, C. G., Luznik, L., & Gojo, I. (2017) · Current Drug Targets · doi:10.2174/1389450116666150518095346 · Cited by 47

CD28/CTLA‐4/B7 costimulatory pathway blockade affects regulatory T‐cell function in autoimmunity

Vogel, I., Kasran, A., Cremer, J., Kim, Y., Boon, L., Gool, S. W. V., & Ceuppens, J. L. (2015) · European Journal of Immunology · doi:10.1002/eji.201445190 · Cited by 47

Antigen-specificity using chimeric antigen receptors: the future of regulatory T-cell therapy?

Boardman, D. A., Maher, J. F., Lechler, R. I., Smyth, L. A., & Lombardi, G. (2016) · Biochemical Society Transactions · doi:10.1042/bst20150247 · Cited by 48

Immune checkpoint inhibitors for nonsmall cell lung cancer treatment

Chen, Y. (2016) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2016.08.005 · Cited by 47

An expanding stage for commensal microbes in host immune regulation

Shi, Y., & Mu, L. (2017) · Cellular and Molecular Immunology · doi:10.1038/cmi.2016.64 · Cited by 46

Targeting metabolic reprogramming in metastatic melanoma: The key role of nicotinamide phosphoribosyltransferase (NAMPT)

Audrito, V., Managò, A., Gaudino, F., & Deaglio, S. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.001 · Cited by 47

Photothermal therapies to improve immune checkpoint blockade for cancer

Balakrishnan, P. B., Sweeney, E. E., Ramanujam, A. S., & Fernandes, R. (2020) · International Journal of Hyperthermia · doi:10.1080/02656736.2020.1797190 · Cited by 48

The roles of exosomal immune checkpoint proteins in tumors

Cheng, X., Li, H., Li, R., Yin, L., Zhang, H., Huang, Z., Cheng, Z., Li, J., Wang, Z.-H., & Peng, H. (2021) · Military Medical Research · doi:10.1186/s40779-021-00350-3 · Cited by 48

Regulatory T cells in autoimmune kidney diseases and transplantation

Mikami, N., & Sakaguchi, S. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00733-w · Cited by 46

Soluble CTLA-4 regulates immune homeostasis and promotes resolution of inflammation by suppressing type 1 but allowing type 2 immunity

Osaki, M., & Sakaguchi, S. (2025) · Immunity · doi:10.1016/j.immuni.2025.03.004 · Cited by 49

Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy

Datta, J., Berk, E., Cintolo, J. A., Xu, S., Roses, R. E., & Czerniecki, B. J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00271 · Cited by 47

Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy

Liechtenstein, T., Dufait, I., Lanna, A., Breckpot, K., & Escors, D. (2012) · Immunology Endocrine & Metabolic Agents - Medicinal Chemistry · doi:10.2174/187152212802001875 · Cited by 47

Impact of the CTLA‐4/CD28 axis on the processes of joint inflammation in rheumatoid arthritis

Körmendy, D., Hoff, H., Hoff, P., Bröker, B. M., Burmester, G. R., & Brunner-Weinzierl, M. C. (2012) · Arthritis & Rheumatism · doi:10.1002/art.37714 · Cited by 46

Targeting CD8 + T-cell Tolerance for Cancer Immunotherapy

Jackson, S. R., Yuan, J., & Teague, R. M. (2014) · Immunotherapy · doi:10.2217/imt.14.51 · Cited by 47

Does the PI3K pathway promote or antagonize regulatory T cell development and function?

Soond, D. R., Slack, E. C. M., Garden, O. A., Patton, D. T., & Okkenhaug, K. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00244 · Cited by 50

Targeting the B7 Family of Co-Stimulatory Molecules

Podojil, J. R., & Miller, S. D. (2012) · BioDrugs · doi:10.1007/s40259-012-0001-6 · Cited by 48

Functional Characterization of T Cell Populations in a Mouse Model of Chronic Obstructive Pulmonary Disease

Eppert, B. L., Wortham, B. W., Flury, J. L., & Borchers, M. T. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1202442 · Cited by 46

Inhibition of Acid Sphingomyelinase Allows for Selective Targeting of CD4+ Conventional versus Foxp3+ Regulatory T Cells

Hollmann, C., Werner, S., Avota, E., Reuter, D., Japtok, L., Kleuser, B., Gulbins, E., Becker, K. A., Schneider‐Schaulies, J., & Beyersdorf, N. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600691 · Cited by 46

DOCK8 enforces immunological tolerance by promoting IL-2 signaling and immune synapse formation in Tregs

Janssen, E., Kumari, S., Tohmé, M., Ullas, S., Barrera, V., Tas, J. M. J., Castillo‐Rama, M., Bronson, R. T., Usmani, S. M., Irvine, D. J., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.94298 · Cited by 46

“Immune TOR-opathies,” a Novel Disease Entity in Clinical Immunology

Jung, S., Gámez-Díaz, L. Y., Proietti, M., & Grimbacher, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00966 · Cited by 46

Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story

Piro, G., Carbone, C., Carbognin, L., Pilotto, S., Ciccarese, C., Iacovelli, R., Milella, M., Bria, E., & Tortora, G. (2019) · Cancers · doi:10.3390/cancers11101525 · Cited by 47

Regulation of CTLA‐4 recycling by LRBA and Rab11

Janman, D., Hinze, C., Kennedy, A., Halliday, N., Waters, E., Williams, C., Rowshanravan, B., Hou, T. Z., Minogue, S., Qureshi, O., et al. (2021) · Immunology · doi:10.1111/imm.13343 · Cited by 48

Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions

Haddad, A. F., Young, J. S., Gill, S. A., & Aghi, M. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.019 · Cited by 47

Tregs in transplantation tolerance: role and therapeutic potential

Cassano, A., Chong, A. S., & Alegre, M. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1217065 · Cited by 45

Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment

Qiu, J., Cheng, Z., Jiang, Z., Gan, L., Zhang, Z., & Xie, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105490 · Cited by 53

Immune therapy of melanoma: Overview of therapeutic vaccines

Payandeh, Z., Yarahmadi, M., Nariman‐Saleh‐Fam, Z., Tarhriz, V., Islami, M., Aghdam, A. M., & Eyvazi, S. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28181 · Cited by 45

Treg-mediated prolonged survival of skin allografts without immunosuppression

Pilat, N., Wiletel, M., Weijler, A. M., Steiner, R., Mahr, B., Warren, J. A., Corpuz, T. M., Wekerle, T., Webster, K. E., & Sprent, J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903165116 · Cited by 45

Genomic profiling of T-cell activation suggests increased sensitivity of memory T cells to CD28 costimulation

Glinos, D. A., Soskic, B., Williams, C., Kennedy, A., Jostins, L., Sansom, D. M., & Trynka, G. (2020) · Genes and Immunity · doi:10.1038/s41435-020-00118-0 · Cited by 47

Tumor resident regulatory T cells

Glasner, A., & Plitas, G. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101476 · Cited by 47

Abnormal alternative splicing promotes tumor resistance in targeted therapy and immunotherapy

Deng, K., Yao, J., Huang, J., Ding, Y., & Zuo, J. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101077 · Cited by 45

Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future

Zhang, Z., Tan, X., Jiang, Z., Wang, H., & Yuan, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1031527 · Cited by 46

Emerging trends and therapeutic applications of monoclonal antibodies

Ramaiah, M. J., Nalluri, H. P., Reddy, P. N., Sainath, S. B., Kumar, N. S. S., Sai Kiran, G. V. S. D., Dhiman, R., Chamarthy, S., Komaragiri, R. R., Manyam, R. R., et al. (2024) · Gene · doi:10.1016/j.gene.2024.148607 · Cited by 45

Suppression of Antigen-Specific T Cell Responses by the Kaposi's Sarcoma-Associated Herpesvirus Viral OX2 Protein and Its Cellular Orthologue, CD200

Misstear, K., Chanas, S. A., Rezaee, S. A., Colman, R., Quinn, L. L., Long, H. M., Goodyear, O. C., Lord, J. M., Hislop, A. D., & Blackbourn, D. J. (2012) · Journal of Virology · doi:10.1128/jvi.07168-11 · Cited by 44

Determinants of Resistance to Checkpoint Inhibitors

Tran, L. L., & Theodorescu, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051594 · Cited by 43

Aryl hydrocarbon receptor activation ameliorates experimental colitis by modulating the tolerogenic dendritic and regulatory T cell formation

Cui, X., Ye, Z., Wang, D., Yang, Y., Jiao, C., Ma, J., Tang, N., & Zhang, H. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00780-z · Cited by 45

The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma

Brandi, N., & Renzulli, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108598 · Cited by 43

Murine regulatory T cells differ from conventional T cells in resisting the CTLA-4 reversal of TCR stop-signal

Lu, Y., Schneider, H., & Rudd, C. E. (2012) · Blood · doi:10.1182/blood-2012-04-421420 · Cited by 44

Cell-mediated immunity to human CMV infection: a brief overview

Terrazzini, N., & Kern, F. (2014) · F1000Prime Reports · doi:10.12703/p6-28 · Cited by 42

Co‐expression of LAG 3 and TIM 3 identifies a potent Treg population that suppresses macrophage functions in colorectal cancer patients

Ma, Q., Liu, J., Wu, G., Teng, M., Wang, S., Cui, M., & Li, Y. (2018) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12992 · Cited by 46

Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again

Bucktrout, S. L., Bluestone, J. A., & Ramsdell, F. (2018) · Genome Medicine · doi:10.1186/s13073-018-0588-4 · Cited by 47

Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability

Narisawa, M., Kubo, S., Okada, Y., Yamagata, K., Nakayamada, S., Sakata, K., Yamaoka, K., & Tanaka, Y. (2020) · Bone · doi:10.1016/j.bone.2020.115616 · Cited by 43

Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma

Wang, X., Zuo, D., Sarkar, D., & Fisher, P. B. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.629187 · Cited by 44

Once upon a prime: DCs shape cancer immunity

Zagorulya, M., & Spranger, S. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.10.006 · Cited by 46

Regulatory T lymphocytes as a therapy for ischemic stroke

Wang, M., Thomson, A., Yu, F., Hazra, R., Junagade, A., & Hu, X.-M. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00975-z · Cited by 40

The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances

Chen, H., Yang, H., Guo, L., & Sun, Q. (2025) · MedComm · doi:10.1002/mco2.70412 · Cited by 47

CTLA4Ig Inhibits Effector T Cells through Regulatory T Cells and TGF-β

Deppong, C. M., Bricker, T. L., Rannals, B. D., van Rooijen, N., Hsieh, C., & Green, J. M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300830 · Cited by 42

MALT1 Proteolytic Activity Suppresses Autoimmunity in a T Cell Intrinsic Manner

Demeyer, A., Skordos, I., Driege, Y., Kreike, M., Hochepied, T., Baens, M., Staal, J., & Beyaert, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01898 · Cited by 42

Coming in from the cold: overcoming the hostile immune microenvironment of medulloblastomaPreprint

Eisemann, T., & Wechsler‐Reya, R. J. (2022) · Genes & Development · doi:10.1101/gad.349538.122 · Cited by 44

Gene therapy with regulatory T cells: A beneficial alliance

Biswas, M., Kumar, S. R. P., Terhorst, C., & Herzog, R. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00554 · Cited by 41

Trogocytosis and cross-dressing in antigen presentation

Schriek, P., & Villadangos, J. A. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102331 · Cited by 41

A review concerning the breast cancer-related tumour microenvironment

Rodríguez-Bejarano, O. H., Parra-López, C., & Patarroyo, M. A. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104389 · Cited by 47

CD4 T cell depletion substantially augments the rescue potential of PD-L1 blockade for deeply exhausted CD8 T cells

Penaloza-MacMaster, P., Provine, N., Blass, E., & Barouch, D. (2015) · Journal of Immunology · doi:10.4049/jimmunol.1403237 · Cited by 38

Ipilimumab (Yervoy) and the TGN1412 catastrophe

Bakács, T., Mehrishi, J. N., & Moss, R. W. (2011) · Immunobiology · doi:10.1016/j.imbio.2011.07.005 · Cited by 41

A Transendocytosis Perspective on the CD28/CTLA-4 Pathway

Soskic, B., Qureshi, O. S., Hou, T., & Sansom, D. M. (2014) · Advances in immunology · doi:10.1016/b978-0-12-800147-9.00004-2 · Cited by 43

Unbalanced Immune System: Immunodeficiencies and Autoimmunity

Giardino, G., Gallo, V., Prencipe, R., Gaudino, G., Romano, R., CATALDIS, M. D., Lorello, P., Palamaro, L., Giacomo, C. D., Capalbo, D., et al. (2016) · Frontiers in Pediatrics · doi:10.3389/fped.2016.00107 · Cited by 41

A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer

Kreuzinger, C., Geroldinger, A., Smeets, D., Braicu, E. I., Sehouli, J., Koller, J., Wolf, A. M., Darb‐Esfahani, S., Joehrens, K., Vergote, I. B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1159 · Cited by 41

CTLA-4-mediated trans-endocytosis in the control of T cell co-stimulation

Ovcinnikovs, V. (2018) · UCL Discovery (University College London)

Investigating transendocytosis mediated by CTLA4

Nguyen, L. (2023) · UNSWorks (University of New South Wales, Sydney, Australia) · doi:10.26190/unsworks/24962

CTLA4 depletes T cell endogenous and trogocytosed B7 ligands via cis-endocytosis

Xu, X., Dennett, P., Zhang, J., Sherrard, A., Zhao, Y., Masubuchi, T., Bui, J. D., Chen, X., & Hui, E. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221391 · Cited by 56

Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation

Kennedy, A., Waters, E., Rowshanravan, B., Hinze, C., Williams, C., Janman, D., Fox, T. A., Booth, C., Pesenacker, A. M., Halliday, N., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01289-w · Cited by 227

Molecular and Cellular Functions of CTLA-4

Coillie, S. V., Wiernicki, B., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_2 · Cited by 259